TY - JOUR
T1 - The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19
T2 - A systematic review and meta-analysis
AU - Harapan, Harapan
AU - Fajar, Jonny Karunia
AU - Supriono, Supriono
AU - Soegiarto, Gatot
AU - Wulandari, Laksmi
AU - Seratin, Fiha
AU - Prayudi, Nyoman Gede
AU - Dewi, Dara Puspita
AU - Monica Elsina, Maria Theresia
AU - Atamou, Lasarus
AU - Wiranata, Sinta
AU - Aprianto, Dhito Pemi
AU - Friska, Erlin
AU - Sari Firdaus, D. Fitria
AU - Alaidin, Makdum
AU - Wardhani, Firdha Aprillia
AU - Husnah, Milda
AU - Hidayati, Nurdina Wahyu
AU - Hendriyanti, Yeni
AU - Wardani, Kristia
AU - Evatta, Arde
AU - Manugan, Reizal Audi
AU - Pradipto, Wiryawan
AU - Rahmawati, Ade
AU - Tamara, Fredo
AU - Mahendra, Aditya Indra
AU - Nainu, Firzan
AU - Santoso, Budi
AU - Irawan Primasatya, Chandra Adi
AU - Tjionganata, Nindy
AU - Budiman, Hendarto Arif
N1 - Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2022/5
Y1 - 2022/5
N2 - The data on the predictors and prognosis of acute liver injury (ALI) among patients in coronavirus disease 2019 (COVID-19) patients are limited. The aim of this study was to determine the prevalence, predictors and outcomes of ALI among patients with COVID-19. A systematic review was conducted up to 10 June 2021. The relevant papers were searched from PubMed, Embase, Cochrane and Web of Science, and the data were analysed using a Z test. A total of 1331 papers were identified and 16 papers consisting of 1254 COVID-19 with ALI and 4999 COVID-19 without ALI were analysed. The cumulative prevalence of ALI among patients with COVID-19 was 22.8%. Male and having low lymphocyte levels were more likely to be associated with ALI compared with female and having higher lymphocyte level, odds ratio (OR): 2.70; 95% confidence interval (CI): 2.03, 3.60 and mean difference (MD) −125; 95% CI: −207, −43, respectively. COVID-19 patients with ALI had higher risk of developing severe COVID-19 compared with those without ALI (OR: 3.61; 95% CI: 2.60, 5.02). Our findings may serve as the additional evaluation for the management of ALI in COVID-19 patients.
AB - The data on the predictors and prognosis of acute liver injury (ALI) among patients in coronavirus disease 2019 (COVID-19) patients are limited. The aim of this study was to determine the prevalence, predictors and outcomes of ALI among patients with COVID-19. A systematic review was conducted up to 10 June 2021. The relevant papers were searched from PubMed, Embase, Cochrane and Web of Science, and the data were analysed using a Z test. A total of 1331 papers were identified and 16 papers consisting of 1254 COVID-19 with ALI and 4999 COVID-19 without ALI were analysed. The cumulative prevalence of ALI among patients with COVID-19 was 22.8%. Male and having low lymphocyte levels were more likely to be associated with ALI compared with female and having higher lymphocyte level, odds ratio (OR): 2.70; 95% confidence interval (CI): 2.03, 3.60 and mean difference (MD) −125; 95% CI: −207, −43, respectively. COVID-19 patients with ALI had higher risk of developing severe COVID-19 compared with those without ALI (OR: 3.61; 95% CI: 2.60, 5.02). Our findings may serve as the additional evaluation for the management of ALI in COVID-19 patients.
KW - COVID-19
KW - acute liver injury
KW - outcome
KW - predictor
KW - prevalence
UR - http://www.scopus.com/inward/record.url?scp=85116888408&partnerID=8YFLogxK
U2 - 10.1002/rmv.2304
DO - 10.1002/rmv.2304
M3 - Review article
AN - SCOPUS:85116888408
SN - 1052-9276
VL - 32
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
IS - 3
M1 - e2304
ER -
